ArticleJournal of the American Heart Association2026
Prevalence and Incidence of Heart Failure Phenotypes Among Transgender and Gender-Diverse Adults in the United States.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inclusive cardiovascular care for sexual and gender minority populations.Nature reviews. Cardiology · 2026Article
- Twenty years of sex and gender science in health research: a policy statement from the Organization for the Study of Sex Differences.Biology of sex differences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevalent and incident heart failure (HF) and its comorbidities have not been characterized in transgender and gender-diverse (TGD) populations. This study determines the prevalence and incidence of HF phenotypes by gender identity.
methodsA retrospective cohort analysis was performed using deidentified administrative claims from the Optum Labs Data Warehouse (2006-2022). TGD adults and a sample of demographically similar cisgender comparators were identified using a validated algorithm, and gender identity was categorized as cisgender man, cisgender woman, transmasculine, transfeminine, or unclassified TGD. Prevalent and incident HF, including systolic, diastolic, and unclassified phenotypes, were assessed using diagnosis codes. Multivariable logistic and Cox regression models adjusted for age and comorbidities evaluated associations between gender identity and HF.
resultsIn this cohort of 57 471 TGD individuals and 298 213 demographically similar cisgender comparators, 17 898 TGD people (31.1%) were transmasculine, 9652 (16.8%) were transfeminine, and 29 921 (52.1%) had unclassified TGD identity. In adjusted models, transmasculine people experienced less prevalent systolic HF than cisgender men (odds ratio, 0.37 [98.75% CI, 0.17-0.83]) and women (odds ratio, 0.42 [98.75% CI, 0.19-0.92]). Transmasculine people experienced less incident diastolic HF relative to cisgender men (hazard ratio [HR], 0.65 [98.75% CI, 0.51-0.82]) and women (HR, 0.66 [98.75% CI, 0.52-0.83]). Transfeminine people experienced more incident diastolic HF than cisgender men (HR, 1.36 [98.75% CI, 1.05-1.77]) and women (HR, 1.38 [98.75% CI, 1.07-1.79]).
conclusionsPrevalent systolic HF and incident diastolic HF differed by gender identity after adjustment for age and clinical comorbidities. Further research is needed to identify underrecognized sex- and gender-based HF risk modifiers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.